FDA approves Alnylam’s ultra-rare disease drug Oxlumo
pharmaphorum
NOVEMBER 24, 2020
The disease is also difficult to diagnose and often takes around six years before doctors correctly identify it. Alnylam’s Givlaari, FDA-approved a year ago for acute hepatic porphyria, costs $575,000 per year at full price in the US, although after discounts the figure is more likely to be in the region of $442,000 per year.
Let's personalize your content